Patents by Inventor Richard Schmiesing

Richard Schmiesing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-(pyridine-4-yl)-N-(quinuclidin-2-yl)thiazole-4-carboxide nicotinic acetylcholine receptor ligands
    Patent number: 7491734
    Abstract: Compounds of formula I: wherein A, D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: February 17, 2009
    Assignee: AstraZeneca AB
    Inventors: Eifion Phillips, Richard Schmiesing
  • New Compounds
    Publication number: 20070149563
    Abstract: Compounds of formula I: wherein A, D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
    Type: Application
    Filed: March 1, 2007
    Publication date: June 28, 2007
    Inventors: Eifion Phillips, Richard Schmiesing
  • Compounds
    Patent number: 7214688
    Abstract: Compounds of formula I: wherein A, D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: May 8, 2007
    Assignee: AstraZeneca AB
    Inventors: Eifion Phillips, Richard Schmiesing
  • Non-amide nonanes
    Publication number: 20070043031
    Abstract: Compounds of Formula I: and pharmaceutically-acceptable salts thereof, wherein Q, E and D are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them and uses of them for diagnostic and analytic purposes.
    Type: Application
    Filed: September 24, 2004
    Publication date: February 22, 2007
    Applicant: AstraZeneca AB
    Inventors: Glen Ernst, Eifion Phillips, Richard Schmiesing
  • Compounds
    Publication number: 20060128749
    Abstract: Compounds of formula I: wherein A, D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
    Type: Application
    Filed: January 5, 2006
    Publication date: June 15, 2006
    Inventors: Eifion Phillips, Richard Schmiesing
  • Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists
    Publication number: 20060052368
    Abstract: Nicotinic acetylcholine receptor agonists of formula I wherein a, b, c, D and R are as defined in the specification, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: August 13, 2003
    Publication date: March 9, 2006
    Inventors: Glen Ernst, Eifion Phillips, Richard Schmiesing
  • Compounds
    Patent number: 7001914
    Abstract: Compounds of formula I: wherein A, D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: February 21, 2006
    Assignee: AstraZeneca AB
    Inventors: Eifion Phillips, Richard Schmiesing
  • N-azabicyclo-amide derivatives
    Patent number: 6683090
    Abstract: Compounds of the general formula I wherein A represents: D represents oxygen, or sulfur and R1, R2 and R3 are as defined in the specification, enantiomers thereof, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: January 27, 2004
    Assignee: Astrazeneca AB
    Inventors: Michael Balestra, George Mullen, Eifion Phillips, Richard Schmiesing
  • Quinuclidine acrylamides
    Patent number: 6642246
    Abstract: Compounds of formula I wherein A represents: and R, R1, R2, R3 and R4 are as defined in the specification, pharmaceutically-cceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: November 4, 2003
    Assignee: Astrazeneca AB
    Inventor: Richard Schmiesing
  • Compounds
    Publication number: 20030008867
    Abstract: Compounds of formula I: 1
    Type: Application
    Filed: April 15, 2002
    Publication date: January 9, 2003
    Inventors: Eifion Phillips, Richard Schmiesing